Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: Overview of 42 trials involving 12,000 randomised children

Lancet

Volumn 347, Issue 9018, 1996, Pages 1783-1788

  Richards, S ^a   Gray, R ^a   Peto, R ^a   Gaynon, P ^a   Masera, G ^a   Pession, A ^a   Rondelli, R ^a   Valsecchi, M G ^a   Reiter, A ^a   Riehm, H ^a   Schrappe, M ^a   McIntyre, O R ^a   Bleyer, A ^a   Cairo, M ^a   Reaman, G ^a   Sather, H ^a   Trigg, M ^a   Auclerc, M F ^a  

^a CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISONE; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; HUMAN; LYMPHATIC LEUKEMIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PATIENT CODING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SURVIVAL; TREATMENT OUTCOME;

EID: 10144246581     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91615-3     Document Type: Note

References (36)

1. Peto R. Why do we need systematic overviews of randomized trials? Stat Med 1987; 6: 233-40.
2. Peto R, Collins R, Gray R, Parish S. Large-scale randomized evidence: large, simple trials and overviews of trials. In: Weatherall DJ, Warrell DA, Ledingham JGG, eds. Oxford textbook of medicine 3rd ed. Oxford University Press, 1966; vol I: 21-32.
3. Clarke MJ, Stewart LA. Obtaining data from randomised controlled trials: how much do we need for reliable and informative metaanalysis? BMJ 1994; 309: 1007-10.
4. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer, vol 1: worldwide evidence 1985-1990. Oxford: Oxford University Press, 1990.
5. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 320-31.
6. Schrappe M, Beck J, Brandeis WE, et al. Die Behandlung der akuten lymphoblastischen Leukämie im Kindes-und Jugendalter: Ergebnisse der multizentrischen Therapiestudie ALL-BFM-81. Klin Pädiat 1987; 199: 133-50.
7. Riehm H, Gadner H, Henze G, et al. Results and significance of six randomized trials in four consecutive ALL-BFM Studies. Haem Blood Trans 1990; 33: 439-50.
8. Aur R, Simone J, Hustu HO, et al. Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood 1971; 37: 272-81.
9. Medical Research Council Working Party on Leukaemia in Childhood. Treatment of acute lymphoblastic leukaemia: effect of variation in length of treatment on duration of remission. BMJ 1977; ii: 495-97.
10. Medical Research Council Working Party on Leuklaemia in Childhood. Effects of varying radiation schedule, cyclophosphamide treatment, and duration of treatment in acute lymphoblastic leukaemia. BMJ 1978; ii: 787-91.
11. Medical Rsearch Council Working Party on Leukaemia in Childhood. Duration of chemotherapy in childhood acute lymphoblastic leukaemia. Med Ped Oncol 1982; 10: 511-20.
12. Chessells JM, Durrant J, Hardy RM, Richards SM on behalf of the Working Party on Leukaemia in Childhood. Medical Research Council Leukaemia Trial - UKALL V: an attempt to reduce the immunosuppressive effects of therapy in childhood acute lymphoblastic leukaemia. J Clin Oncol 1986; 4: 1758-64.
13. Bleyer WA. Remaining problems in the staging and treatment of childhood lymphoblastic leukemia. Am J Ped Hem Oncol 1989; 11: 371-79.
14. Paolucci G, Masera G, Vecchi V, et al. Treating childhood acute lymphoblastic leukaemia (ALL): Summary of ten years' experience in Italy. Med Ped Oncol 1989; 17: 83-91.
15. Eden OB, Lilleyman JS, Richards SM, Shaw MP, Peto J, on behalf of the Working Party on Leukaemia in Childhood. Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII. Br J Haematol 1991; 78: 187-96.
16. Leverger G, Demeocq F, Freycon F, et al. Treatment of childhood acute low-risk lymphoblastic leukemias: Preliminary results of the French ALL Study Group FRALLE 83. Med Fed Oncol 1988; 16: 389 (abstr).
17. Nesbit ME, Sather HN, Robson LL, Ortega J, Hammond GD and the CCSG. Randomized study of 3 years versus 5 years of chemotherapy in childhood acute lymphoblastic leukemia. J Clin Oncol 1983; 1: 308-16.
18. Miller DR, Leikin S, Albo V, Sather HN, Hammond GD. Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol 1989; 7: 316-25.
19. Mauer A, Simone J. The current state of the treatment of childhood acute lymphoblastic leukemia. Cancer Treat Rev 1976; 3: 17-41.
20. Bleyer WA, Coccia PF, Sather HN, et al. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol 1983; 1: 317-25.
21. Bleyer WA, Sather HN, Nickerson HJ, et al. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Children's Cancer Study Group. J Clin Oncol 1991; 9: 1012-21.
22. Henze G, Langermann H-J, Fengler R, et al. Therapiestudie BFM 79/81 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: intensivierte Reinduktionstherapie für Patientengruppen mit unterschiedlichen Rezidivrisiko. Klin Pädiat 1982; 194: 195-203.
23. Holland JF, Glidewell OJ. Chemotherapy, of acute lymphocytic leukemia of childhood. Cancer 1972; 30: 1480-87.
24. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukaemia and intermediate presenting features. A Children's Cancer Group Phase III Trial. J Clin Oncol 1993; 11: 527-37.
25. Chessells JM, Bailey C, Richards SM, and the MRC Working Party on Childhood Leukaemia. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALLX. Lancet 1995; 345: 143-48.
26. Henze G, Fengler R, Reiter A, Ritter J, Riehm H. Impact of early intensive re-induction therapy on event-free survival in children with low-risk acute lymphoblastic leukaemia. Haem Blood Trans 1990; 33: 483-88.
27. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S. Chemotherapy in 998 unselected childhood lymphoblastic leukaemia patients: Results and conclusions of the multicenter trial ALL-BFM-86. Blood 1994; 84: 3122-33.
28. Rowland JH, Glidewell OJ, Sibley RF, et al. Effects of different forms of central nervous system prophylaxis on neuropsychologic function in childhood leukemia. J Clin Oncol 1984; 2: 1327-35.
29. van Eys J, Berry D, Crist W, et al. Treatment intensity and outcome for children with acute lymphocytic leukemia of standard risk. Cancer 1989; 63: 1466-71.
30. Pinkel D, Hernandez K, Borella L, et al. Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer 1971; 27: 247-56.
31. Sackmann-Muriel F, Svarch E, Eppinger-Helft M, et al. Evaluation of intensification and maintenance programs in the treatment of acute lymphoblastic leukemia. Cancer 1978; 42: 1730-40.
32. Sallan SE, Clavell LA, Gelber R, Hitchcock-Bryan S, Cassady JR. A successful therapy program for childhood acute lymphoblastic leukemia: preliminary results of protocol 80-01. In: Wehringer H, ed, Current therapy of leukemia in childhood, Friedrichsdorf/Taunus. Milupa AG, 1984; 35-43.
33. Aur RJA, Simone JV, Hustu HO, Verzosa MS. A comparative study of central nervous system irradiation and intensive chemotherapy early in remission of childhood acute lymphocytic leukemia. Cancer 1972; 29: 381-91.
34. Aur R, Simone J, Verzosa M, et al. Childhood acute lymphocytic leukemia. Cancer 1978; 42: 2123-34.
35. Pui C-H, Aur RJA, Bowman WP, et al. Failure of late intensification therapy to improve a poor result in childhood lymphoblastic leukemia. Cancer Res 1984; 44: 3593-98.
36. Medical Research Council Working Party on Leukaemia in Childhood. The treatment of acute lymphoblastic leukaemia (ALL) in childhood, UKALL III: The effects of added cytosine arabinoside and/or asparaginase, and a comparison of continuous or discontinuous mercaptopurine in regimens for standard risk ALL. Med Ped Oncol 1982; 10: 501-10.